Objectives: We investigated whether catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with eating disorders (EDs). 
Introduction
Eating disorders (EDs) are severe psychiatric conditions characterized by a frequently disabling course and associated with high rates of comorbid psychopathology , medical complications (Shuttleworth, Sharma, Lal, & Allan, 2016; and specific neuropsychological profiles (Treasure, Claudino, & Zucker; Van den Eynde et al., 2011) .
In the last decades, major advances have been made in the understanding of the neurobiology of EDs, with increasing knowledge in their pathophysiology (Veronese et al., 2015) , genetic and epigenetic profiles (Zeynep Yilmaz, Hardaway, & Bulik, 2015) , structural and functional brain alterations Frank, 2015) and executive functioning impairment (Tenconi et al., 2010) . Because dopamine is implicated in appetite regulation, eating and motor behaviours, emotional functioning and cognitive processes, the literature paid a great deal of attention to the possible role of this neurotransmitter in the pathophysiology of EDs.
In particular, the dysregulation of frontostriatal dopaminergic circuit has been considered a key factor in explaining the affective and cognitive alterations observed in anorexia nervosa (AN) and bulimia nervosa (BN) patients because these neural pathways support self-regulatory capacities and reward-based learning (Berner & Marsh, 2014; Kaye, Fudge, & Paulus, 2009) . The role of genes implicated in dopaminergic prefrontal signalling and metabolism is therefore of particular interest in EDs and has been investigated in several studies.
Among the genes involved in dopamine prefrontal metabolism, catechol-O-methyltransferase (COMT) appears to play a pivotal role in the modulation of frontostriatal networks because it seems to have an important role in the modulation of neurocognitive functioning (Savitz, Solms, & Ramesar, 2006) . The Val158Met is by far the most studied COMT polymorphism, as it modifies the thermal stability of the gene and thus its enzymatic activity, with complex consequences on cognitive operations influenced by DA signalling (Dickinson & Elvevåg, 2009) .
The relationship between DA tone in the prefrontal cortex (PFC) and PFC-dependent cognitive performance is characterized by an inverted U-shape, which may be determined by differential effects of D1 and D2 receptor binding (Bilder, Volavka, Lachman, & Grace, 2004) . In particular, in the presence of the COMT Met allele, DA levels in the PFC increase and the resulting higher tonic D1 stimulation leads to beneficial effects on the stability of mental representations but at the cost of disadvantageous consequences on cognitive flexibility and working memory update abilities. Conversely, the COMT Val allele is associated with decreased DA concentrations and a low D1/high D2 state, which is associated not only with greater behavioural flexibility but also with higher impulsivity and risky decision making (Bilder et al., 2004) .
The study of the Val158Met COMT genotype in EDs is particularly interesting because the effects of the COMT enzyme are influenced by oestrogen levels. Estrogens inhibit COMT mRNA expression, reducing the effect of the COMT enzyme activity and of the COMT genotype in women compared with men (Harrison & Tunbridge, 2008; Jacobs & D'Esposito, 2011) . Because oestrogen levels decrease greatly during starvation, underweight patients with AN represent a unique opportunity to study the interaction between oestrogen levels and the COMT genotype.
Several studies have investigated the relationship between AN and the COMT Val158Met polymorphism, while less data are available about BN. The most recent meta-analysis on COMT genotype and ED was based on literature searches conducted up to April 2011 (Brandys et al., 2012) and showed that the Val158Met polymorphism was not associated with AN. However, since then, additional studies have explored the potential association between EDs and COMT, and studies evaluating the relevance of COMT genotype in BN have not been meta-analysed to date. Therefore, the aim of the present meta-analysis was to test whether COMT Val158Met polymorphism is associated with ED as a broad category, or specifically with AN or BN, summarizing all published evidence and adding novel data from the 'Biobanca Veneta per i Disturbi Alimentari' biobank (BIO.VEDA; .
Methods
'Biobanca Veneta per i Disturbi Alimentari' (BIO. VEDA) data The BIO.VEDA sample included 920 lifetime cases of AN (n = 562) and/or BN (n = 358) according to Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria (A.P.A., 2013) and 261 healthy controls (HCs). These patients were recruited from five Eating Disorder Units of the Veneto region, Italy. The BIO.VEDA project is funded by the Veneto Region, and its main aim is to establish a genetic biobank for EDs. The following inclusion criteria were used: a lifetime diagnosis of AN or BN according to DSM-5, age > 14 years old, patients' and parental (if less than 18 years old) informed consent. The study was approved by local hospital Ethics Committee. The following exclusion criteria were applied: organic comorbidity or major psychiatric comorbidity (bipolar disorder, schizophrenia and major depressive disorder). All participants underwent saliva or blood sampling to collect DNA, which was extracted from 200 μL of whole peripheral blood, using High Pure PCR Template Preparation Kit (Roche Diagnostics GmbH), or from 500 μL of saliva with Oragene•DNA/saliva Kit (DNA Genotek Inc) according to the manufacturer's instructions.
Procedures for genomic DNA extraction and for the COMT Val158Met polymorphism analysis have been described previously (Favaro et al., 2013) .
Meta-analysis

Search strategy
We conducted an electronic literature search in PubMed and SCOPUS from data base inception until 15 January 2017 for studies investigating COMT Val158Met genotype or allele frequencies in EDs and a control group. The following search key was used: 'eating disorders' (MeSH terms) OR 'eating' (all fields) AND 'disorders' (all fields) OR 'eating disorders' (all fields) OR 'anorexia nervosa' OR 'bulimia nervosa' OR 'binge eating disorders' AND 'COMT' (all fields) OR 'transferases' (MeSH terms) OR 'transferases' (all fields) OR 'transferase' (all fields). Equivalent search terms were used in Scopus. Reference lists of included articles and those relevant to the topic were hand-searched for identification of additional potentially relevant articles.
Study selection
Included were only peer-reviewed studies that (i) included patients diagnosed with EDs according to DSM-5 criteria and (ii) reported COMT Val158Met genotype or allele frequencies in patients with EDs and a control group. Previous reviews and meta-analyses were full-text read to identify further studies. No language restrictions were applied.
Data extraction and quality assessment
Two authors (E.C. and D.G.) independently extracted data from selected studies into a standardized Microsoft Excel spreadsheet. Any disagreement was resolved by consensus with a third author (A.F.). The following information was extracted: (i) study population characteristics (e.g. sample size, demographics, diagnostic criteria and subtype of AN or BN, comorbidities, medications and anthropometric data); (ii) genotype or allele frequencies in patients and controls; (iii) quality indicators used for the STROBE assessment; and (iv) Hardy-Weinberg equilibrium (HWE). Whenever studies had the same authors or affiliation or close publication year, we contacted authors to verify that data were not referring to the same sample. Whenever genotype or allele frequencies were not available, we contacted authors to ask for unpublished data at least twice. We ran the following comparisons within patients and within controls: (i) Met/Met, Val/Val and Val/Met genotype frequency differences among AN, BN or EDs and HC and (ii) Val and Met frequency differences among AN, BN or EDs and HC.
The Newcastle-Ottawa Scale (Wells et al., 2013 ) was used to assess the quality of the included studies.
Meta-analysis
We meta-analysed comparisons reported in at least two studies, in order to provide the maximum number of meta-analysable outcomes.
The meta-analysis was performed by using REVIEW MANAGER version 5.3 for Windows [Review Manager (RevMan, 2014) (computer program) version 5.3. Copenhagen: The Nordic Cochrane Centre]. When combining studies, the random effects model (DerSimonian & Laird, 1986 ) was used to account for study heterogeneity. For dichotomous data, odds ratio (OR) with its 95% confidence interval (CI) was used. Heterogeneity was assessed with the Cochran Q and I 2 statistics for each analysis, with I 2 ≥ 50 indicating high heterogeneity (Higgins, Thompson, Deeks, & Altman, 2003) . Publication bias was assessed via visual inspection of funnel plots and Egger's test (Egger, Davey Smith, Schneider, & Minder, 1997) , with comprehensive meta-analysis (CMA. n.d.). In order to perform a sensitivity analysis and test for publication bias, we performed the trim and fill procedure to remove the most extreme small studies from the positive side of the funnel plot and recalculated the effect size at each iteration, until the funnel plot was symmetric around the (new) effect size (Duval & Tweedie, 2000) .
We included BIO.VEDA group data in the meta-analysis. HWE was tested in each study separately with both χ 2 test and relative excess heterozygosity test (Ziegler, Van Steen, & Wellek, 2011 ). Finally, we tested the pooled relative excess heterozygosity test from all included studies by using a random effects model, which is a more appropriate tool than the χ 2 test to test HWE in metaanalyses (Ziegler et al., 2011) .
Results
Search results (Figure 1)
We identified 354 studies through our electronic search, plus three additional references from the hand-searched bibliography of relevant papers. After duplicate removal, the title and abstract of 312 papers were screened, and 292 were excluded. We assessed full text of 20 papers and excluded 10 additional references for different reasons specified in Figure 1 . Finally, we included in the meta-analysis 10 studies (Brandys et al., 2012; DmitrzakWeglarz, Rybakowski, Czerski, Hauser, & Rajewski, 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim, Kim, & Kim, 2010; Mikolajczyk, Grzywacz, & Characteristics of included studies (Table 1) The main features of the included studies are summarized in Table 1 . Overall, we analysed data from 3541 patients with EDs and 3684 controls not affected by any ED. Among the based on three studies) and 20.2 ± 1.5 kg/m 2 for controls. Seven studies only included patients with AN, one study included patients with BN, and three studies included both patients with AN and BN. Only one study reported data about lifetime comorbidity, and one study reported information about concomitant medication treatment. In all studies, the COMT genotype was in HWE, except one where such information was not reported.
All studies compared patients with ED with nonaffected HCs (sisters of patients in one study). Eight studies defined ED according to DSM-IV criteria (A.P.A., 2000), while BIO.VEDA data defined ED according to DSM-5 (A.P.A., 2013), and one study each used International Classification of Diseases 10 revision (W.H.O., 1992) or Eating Disorder Examination Questionnaire (Fairburn & Beglin, 1994) 
criteria.
Quality of included studies (Table 1) Overall, the quality was high, with 7 out of 11 studies meeting all quality criteria, 3 studies missing 1, and 1 study missing 2 features instead (Table 1) .
Meta-analysis (Table 2 and Figure 2)
All results of the meta-analyses comparing patients with control groups are reported in Table 2 .
Considering 
Publication bias
Funnel plot visual inspection and Egger's regression test showed the presence of publication bias (1.54, 95% CI 0.46-2.51; p = 0.003) for val/val genotype frequency comparative metaanalysis. However, the trim and fill procedure substantially confirmed our results because looking for missing studies both to the left and to the right of the pooled effect size resulted in no difference in genotype frequency between the two groups.
Discussion
Due to the importance of dopamine signalling for normal human behaviour, the COMT Val158Met SNP is one of the most studied genetic variants in psychiatry (Schacht, 2016) , and its role in influencing cognitive and executive performances has been assessed in several studies (Bruder et al., 2005; Goldberg et al., 2003; Scheggia, Sannino, Scattoni, & Papaleo, 2012) . Given the importance of dopamine metabolism in limbic and executiveassociative pathways and the involvement of striatal and prefrontal circuits in the pathophysiology of EDs, we aimed to metaanalytically evaluate whether the COMT Val158Met genotype differed between ED patients and controls, as this would point to specific pathophysiologic underpinnings of EDs and could possibly point to novel treatment approaches.
However, according to our analyses, there was no signal that COMT Val158Met polymorphisms are associated with AN or BN. Moreover, results were very homogenous and, although publication bias was present, results did not change after trim and fill procedure. Our results are consistent with those of the previous meta-analysis conducted by Brandys and colleagues, which rejected the hypothesis of an association between rs4680 and AN (Brandys et al., 2012) . In addition, our meta-analysis also shows the absence of a significant association with BN or ED as a combined category. BIO.VEDA data, which represent the second largest database analysed up to now considering AN diagnosis and the largest considering BN, were similarly consistent with the results of the other studies included in the meta-analysis. The fact that less studies investigated COMT polymorphisms in BN, compared with AN, is consistent with the more limited neurobiological characterization of BN and with a less homogeneous description of its neuropsychological functioning (Degortes, Tenconi, Santonastaso, & Favaro, 2016; Van den Eynde et al., 2011) . Moreover, the absence of an association between COMT Val158Met genotype and ED mirrors similar results for the serotonin transporter 5-HTTLPR polymorphism, another monoamine modulating single polymorphism as previously reported (Rozenblat et al., 2017; .
Despite the possible role of COMT Val158Met polymorphism in influencing executive functioning and prefrontal connectivity in AN (Favaro et al., 2013) , this genetic variant does not seem to represent a risk factor for the development of EDs. Favaro et al. hypothesized that, due to the estrogens effects, COMT effects on cognitive functioning might be observable only in acute underweight AN patients (Favaro et al., 2013) . From this perspective, it would be useful to explore the complex interaction between this genetic variant and oestrogen levels not only with regard to the risk of developing an ED but also as a factor involved in the maintenance of low BMI and lack of remission. Despite the current negative results, we suggest that the influence that COMT Val158Met genotype can exert on frontostriatal functioning in ED, and its consequences on clinical features, such as treatment response, should be further characterized by specific studies that investigate oestrogen levels and executive functioning as possible mediators of outcome in EDs.
The present study has both strengths and limitations that need to be taken into consideration when interpreting its results. First, one of the strengths is the inclusion of data from the BIO.VEDA biobank, which provided the largest sample of patients affected by BN that has been investigated regarding the COMT Val158Met polymorphism and the second largest sample of patients diagnosed with AN. Second, the BIO.VEDA sample was free from major psychiatric comorbidities (bipolar disorder, schizophrenia and major depressive disorder), removing the possibility of potential biases due to other major psychiatric disorders. Third, this is the first meta-analysis about the association between COMT Val158Met polymorphism and BN. The paucity of data about the role of this genetic variant in the aetiology and in cognitive and executive features of BN points to the need of more studies that investigate these topics. Fourth, our meta-analysis added 4 studies and 2356 subjects compared with the last meta-analysis that focused on AN only. Last but not the least, our results showed low heterogeneity and lacked indication for publication bias, both when pooling EDs together Brandys et al., 2012; Dmitrzak-Weglarz et al., 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 2016; Pinheiro et al., 2010; Yilmaz et al., 2011 7082 Brandys et al., 2012; Dmitrzak-Weglarz et al., 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 2016; Pinheiro et al., 2010; Yilmaz et al., 2011 7082 versus 8174 Odds ratio (M-H, random, 95% CI) Brandys et al., 2012; Dmitrzak-Weglarz et al., 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 2016; Pinheiro et al., 2010; Yilmaz et al., 2011 3541 Brandys et al., 2012; Dmitrzak-Weglarz et al., 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 2016; Pinheiro et al., 2010; Yilmaz et al., 2011 3541 versus 4087 Odds ratio (M-H, random, 95% CI) Brandys et al., 2012; Dmitrzak-Weglarz et al., 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 2016; Pinheiro et al., 2010; Yilmaz et al., 2011 3541 versus 4087 Odds ratio (M-H, random, 95% CI) and when analysing AN and BN separately, which increases the confidence in our conclusions. Several limitations should also be mentioned. First, we acknowledge the lack of studies, which consider the presence of comorbid psychiatric disorders. Second, only few studies included non-Caucasian patients. Thus, our results may not be representative of specific ethnic groups. For example, although studies in a Chinese Han population (Peng et al., 2016) and in Korean subjects (Kim et al., 2010 ) also failed to find significant differences in COMT genotype between patients with EDs and HC, two studies (with an overlapping sample) conducted in an Israeli sample did report a significant association between rs4680 and AN. Nevertheless, overall, the results were consistent and homogenous.
Third, frequently control groups were simply defined as not being affected by ED, without clear exclusion of other organic or psychiatric diseases. Finally, only the BIO.VEDA used the new diagnostic criteria by using DSM-5, yet ED criteria do not vary greatly and this variation is unlikely to have influenced the results to a relevant degree.
In conclusion, in this largest and most comprehensive metaanalysis to date, consistently no association was found between COMT Val158Met polymorphisms and ED, AN or BN. Furthermore, our results support the need to move from candidate gene studies to genome-wide approaches, given the poor ability of the firsts in providing robust and replicable findings.
